UNITY Biotech rises on additional data from eye drug trial

Unity Biotechnology

14/02/2022 15:08

** Shares of eye drug developer  UBX.O  rise 5.7% to $0.96
    ** Co reports 24-week data from early-stage trial testing
its drug UBX1325 to treat eye diseases  urn:newsml:reuters.com:*:nFWN2UP0Z2
    ** In the trial, patients with diabetic macular edema (DME)
and age-related macular degeneration (AMD) showed rapid
improvement in vision
    ** UBX1325 was well tolerated without signs of intraocular
inflammation or other related ocular adversities
    ** Mid-stage studies of UBX1325 currently enroling patients;
co expects 12-week data from study in DME patients by mid-2022
and 16-week data from study in wet AMD in Q4 of 2022
    ** 6 of 8 brokerages rate stock "buy" or higher, 2 "hold";
their median PT is $5.50
    ** Stock has lost ~33% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))